Ansa Biotechnologies
New accelerator entry · 2022-08-20 · the record
Before you sell to, join or invest in Ansa Biotechnologies
MentionFox check on Ansa Biotechnologies: only 1 source on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/yc-ansa-biotechnologies
Check Ansa Biotechnologies before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years.
Ansa Biotechnologies is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: Next-generation DNA synthesis using enzymes. The founders listed are Dan Lin-Arlow (Founder), Sebastian Palluk (Founder) (Y Combinator directory entry, August 20, 2022).
Sell to companies like Ansa Biotechnologies? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2022-08-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ansa Biotechnologies.
Free to see. No signup.
More on Ansa Biotechnologies and the records around it.
Same batch, Healthcare first.
Get an email when Ansa Biotechnologies changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ansa Biotechnologies raises, hires or launches. No email unless you switch it on.
Watch Ansa Biotechnologies →Get the full cited report on Ansa Biotechnologies
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ansa Biotechnologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ansa Biotechnologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ansa Biotechnologies covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ansa BiotechnologiesYou get an alert in MentionFox the next time this company shows up.
If you're behind Ansa Biotechnologies: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Ansa Biotechnologies. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.

https://mentionfox.com/funding/yc-ansa-biotechnologies